FDA Grants Breakthrough Therapy Designation to Bevonescein for Real-Time Nerve Visualization in Head and Neck Surgery
核心洞察
The FDA has granted Breakthrough Therapy Designation to bevonescein as an adjunct for real-time intraoperative visualization of nerves during head and neck surgery in adults.
Bevonescein is an investigational intravenous fluorescent peptide-dye conjugate that binds nerve tissue and is visible to surgeons without a camera or display monitor.
Three completed multicenter, randomized Phase 3 trials showed statistically significant improvement in the co-primary endpoint of Nerve Conspicuity in thyroid, parathyroid, parotid and neck dissection surgery.
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to bevonescein for use as an adjunct in the real-time intraoperative visualization of nerves during head and neck surgical procedures in adults, Alume Biosciences (搜索) announced on September 25, 2026. The designation follows Fast Track designation for the same agent, which the FDA granted in 2022.
Bevonescein is an investigational, intravenously administered fluorescent peptide-dye conjugate that binds to nerve tissue. Because its fluorescent signal falls in the visible spectrum, surgeons can see highlighted nerves directly with their eyes in real time during surgery, without a camera, imaging interface, or display monitor. The drug is given intravenously before surgery and selectively highlights nerve tissue when viewed with fluorescence-capable equipment such as analog surgical microscopes or filter-modified surgical loupes. Bevonescein has not been approved by the FDA or any other regulatory authority, and its safety and efficacy have not been established.
Clinical rationale
Iatrogenic nerve injury (搜索) is the complication the program targets. More than 250,000 head and neck procedures that place critical nerves at risk are performed each year in the United States. Injury to the facial, recurrent laryngeal, or spinal accessory nerves can cause facial paralysis (搜索), voice and airway impairment, or shoulder dysfunction. Current intraoperative nerve monitoring with electromyography can signal nerve electrical activity, but it does not allow surgeons to directly see highlighted nerves during active dissection.
"Iatrogenic nerve injury (搜索) remains one of the most consequential complications for patients undergoing surgical procedures in the head and neck," said Quyen T. Nguyen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Alume Biosciences (搜索) and Professor of Otolaryngology-Head and Neck Surgery and Pharmacology at UC San Diego Health.
Gregory W. Randolph, M.D., Professor of Otolaryngology Head and Neck Surgery, Director of the Thyroid/Parathyroid Endocrine Surgical Division at Massachusetts Eye and Ear Infirmary, Bertucci Endowed Chair in Thyroid Surgical Oncology at Harvard Medical School, and one of the clinical trial principal investigators, said the designation recognizes the potential impact of bevonescein, if approved by the FDA, for patients undergoing procedures where inadvertent nerve injury is a known risk by allowing improved nerve detection and visualization beyond what is available to the surgical eye alone.
Phase 3 program results
Alume has completed three multicenter, prospective, randomized Phase 3 trials of bevonescein in thyroid, parathyroid, parotid, and neck dissection surgery (NCT05377554; NCT06227585). In each trial, the same nerves were assessed under white light alone and under white light plus fluorescence. Bevonescein-enabled fluorescence visualization produced a statistically significant improvement in the co-primary endpoint of Nerve Conspicuity in all three trials. In the pooled analysis, bevonescein also produced statistically significant improvements in visible nerve length and branching delineation, with p values at or below 0.0001 for each. Across the Phase 3 programs, no serious drug-related adverse events were reported.
Phase 3 data were presented at the 2026 American Head and Neck Society meeting in Boston and the 2026 Collegium Otorhinolaryngology Amitiae Sacrum meeting in Groningen, the Netherlands.
Regulatory context
The FDA grants Breakthrough Therapy Designation to expedite the development and review of investigational drugs intended to treat a serious or life-threatening condition. The investigational drug must also have preliminary clinical evidence indicating that it may demonstrate substantial improvement over available therapy on at least one clinically significant endpoint. The designation does not guarantee or provide assurances of FDA approval or a shortened review timeline.
Alume Biosciences (搜索) is a clinical-stage company developing molecularly targeted fluorescent drugs that help surgeons see critical anatomy in real time.